Mylotarg
Showing 1 - 25 of 71
Post Marketing Surveillance (PMS) Study of Mylotarg
Not yet recruiting
- Acute Myeloid Leukemia
- (no location specified)
Apr 12, 2022
Leukemia, Myeloid, Acute Trial in Jerusalem (Vyxeos, Mylotarg)
Recruiting
- Leukemia, Myeloid, Acute
- Vyxeos
- Mylotarg
-
Jerusalem, Yerushalayim, IsraelShaare Zedek Medical Center
Oct 25, 2022
Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)
Active, not recruiting
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Gemtuzumab Ozogamicin
-
Valhalla, New YorkNew York Medical College
Sep 26, 2022
Leukemia, Myeloid, Acute Trial in Canada, United States (VOR33, Mylotarg)
Recruiting
- Leukemia, Myeloid, Acute
- VOR33
- Mylotarg
-
La Jolla, California
- +8 more
Jan 31, 2023
Patients Diagnosed With Acute Myeloid Leukemia Who Received
Completed
- Leukemia, Myeloid, Acute
- Gemtuzumab Ozogamicin
-
New York, New YorkPfizer Investigational Site
Jul 16, 2021
Acute Myeloid Leukemia Trial in Tampa (Vyxeos, Gemtuzumab Ozogamicin)
Recruiting
- Acute Myeloid Leukemia
- Vyxeos
- Gemtuzumab Ozogamicin
-
Tampa, FloridaMoffitt Cancer Center
Sep 23, 2022
Acute Myeloid Leukemia Trial in Memphis (Venetoclax, Azacitidine, Cytarabine)
Not yet recruiting
- Acute Myeloid Leukemia
- Venetoclax
- +9 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Jul 21, 2023
Acute Myeloid Leukemia Trial in Germany (MODULE: conventional chemo (Cytarabine+Daunorubicin) in combination with
Active, not recruiting
- Acute Myeloid Leukemia
- MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO
- +4 more
-
München, Bayern, Germany
- +10 more
Aug 31, 2021
Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)
Active, not recruiting
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Gemtuzumab Ozogamicin
-
Valhalla, New YorkNew York Medical College
Nov 11, 2021
Drug/Agent Toxicity by Tissue/Organ, Leukemia, MDS Trial in Chicago, Kankakee (amifostine trihydrate, cytarabine, mitoxantrone
Withdrawn
- Drug/Agent Toxicity by Tissue/Organ
- +3 more
- amifostine trihydrate
- +2 more
-
Chicago, Illinois
- +3 more
Jan 31, 2023
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Baltimore, Buffalo (Gemtuzumab Ozogamicin,
Recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Gemtuzumab Ozogamicin
- +4 more
-
Baltimore, Maryland
- +1 more
Dec 13, 2022
Novo Acute Myeloid Leukemia Trial in Spain (Mylotarg)
Completed
- Novo Acute Myeloid Leukemia
- Mylotarg
-
Badalona, Barcelona, Spain
- +5 more
Jan 26, 2021
Acute Myeloid Leukemia Trial in New York (CPX-351, Gemtuzumab Ozogamicin)
Recruiting
- Acute Myeloid Leukemia
- CPX-351
- Gemtuzumab Ozogamicin
-
New York, New YorkWeill Cornell Medical College
Dec 21, 2021
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk
Recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +5 more
- Gemtuzumab Ozogamicin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia Trial in New York (Fludarabine, Busulfan,
Completed
- Acute Myelogenous Leukemia
- +2 more
- Fludarabine
- +5 more
-
New York, New YorkColumbia University Medical Center
Aug 4, 2021
Acute Myeloid Leukemia Trial in Seattle (drug, biological, other)
Active, not recruiting
- Acute Myeloid Leukemia
- Cladribine
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 10, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody
Active, not recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Anti-OX40 Agonist Monoclonal Antibody PF-04518600
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jan 25, 2022
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute
Recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +3 more
- Gemtuzumab Ozogamicin
- Liposome-encapsulated Daunorubicin-Cytarabine
-
Houston, TexasM D Anderson Cancer Center
Jun 2, 2021
Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow
Recruiting
- Acute Myeloid Leukemia
- +6 more
- Cladribine
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2022
Acute Myeloid Leukemia Trial in Heidelberg (Bortezomib, Gemtuzumab Ozogamicin)
Recruiting
- Acute Myeloid Leukemia
- Bortezomib
- Gemtuzumab Ozogamicin
-
Heidelberg, Baden-Württemberg, GermanyUniversity Hospital Heidelberg, Internal Medicine V
May 25, 2020
Acute Promyelocytic Leukemia Trial in Worldwide (Mylotarg, Arsenic Trioxide, All-trans retinoic acid)
Recruiting
- Acute Promyelocytic Leukemia
- Mylotarg
- +2 more
-
Brussels, Belgium
- +30 more
Aug 9, 2022
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute
Recruiting
- Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- +9 more
- Cytarabine
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Oct 27, 2021
Acute Myeloid Leukemia Trial in Austria, Germany (Gemtuzumab Ozogamicin (Mylotarg), standard chemo)
Completed
- Acute Myeloid Leukemia
- Gemtuzumab Ozogamicin (Mylotarg)
- standard chemotherapy
-
Graz, Austria
- +59 more
Sep 28, 2021
Leukemia, Myeloid, Acute Trial in United States (VCAR33)
Not yet recruiting
- Leukemia, Myeloid, Acute
- VCAR33
-
La Jolla, California
- +9 more
Aug 14, 2023